T1	intervention 72 126	nanoparticle albumin-bound paclitaxel with bevacizumab
T4	total-participants 907 910	212
T5	total-participants 932 935	208
T6	intervention-participants 944 946	75
T7	intervention-participants 955 957	54
T8	control-participants 966 968	79
T9	outcome 1034 1051	grade ≥ 2 fatigue
T10	outcome 1093 1102	bone pain
T11	iv-bin-percent 1060 1063	46%
T12	iv-bin-percent 1072 1075	62%
T13	cv-bin-percent 1084 1087	62%
T14	iv-bin-percent 1111 1114	11%
T15	iv-bin-percent 1123 1126	23%
T16	cv-bin-percent 1135 1137	5%
T17	outcome 1140 1163	Neurotoxicity grade ≥ 2
T19	outcome 1237 1256	Febrile neutropenia
T22	iv-bin-percent 1338 1341	45%
T23	iv-bin-percent 1350 1353	41%
T24	cv-bin-percent 1362 1365	46%
T25	outcome 1368 1378	Median TTP
T26	iv-cont-median 1409 1419	9.0 months
T27	iv-cont-median 1433 1443	8.0 months
T28	cv-cont-median 1452 1462	5.8 months
T18	outcome 1299 1302	ORR
T20	outcome 1497 1515	antitumor activity
T21	control 652 684	130 mg/m(2) weekly uninterrupted
T3	outcome-Measure 825 856	Time to tumor progression (TTP)
T29	outcome-Measure 861 877	overall survival
T2	outcome-Measure 783 810	overall response rate (ORR)
T30	outcome-Measure 815 823	toxicity
